One-Year Results From the EMBRACE Registry Evaluating the GORE VIABAHN VBX Balloon Expandable Endoprosthesis during BEVAR for Complex Abdominal and Thoracoabdominal Aneurysms
Objective: The stability of bridging stents is critical to ensure the effectiveness and safety of branched endovascular aortic repair (BEVAR) for complex and thoracoabdominal aortic aneurysms (TAAA). The goal of this multicenter registry was to assess the clinical performance and safety of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) as a bridging stent in BEVAR. Methods: The EMBRACE registry is a multicenter study across 14 European centers with retrospective enrollment and prospective follow-up. Patients were divided into BEVAR and fenestrated endovascular aneurysm repair (FEVAR) arms. This analysis reports the BEVAR cohort, which included patients receiving the VBX Stent Graft as a bridging stent for at least 1 visceral vessel. The primary endpoint was patient-level primary patency at 12 months. Secondary endpoints included technical success, reintervention, and target vessel patency assessed annually for up to 5 years. Secondary safety outcomes included major adverse events and aneurysm-related mortality. Results: A total of 165 patients (69.1% male, mean age 72.5 ± 9 years) were enrolled, receiving 454 VBX Stent Grafts (26.0% celiac trunk, 28.9% superior mesenteric artery (SMA), 21.8% left renal, and 23.3% right renal artery). VBX Stent Graft technical success was 99.6%. Thirty-day mortality was 7.9%, with major adverse events in 15.2% (1.8% respiratory failure, 7.3% renal function deterioration, 0.6% bowel ischemia, 4.2% paraplegia, and 1.8% major stroke). Freedom from aneurysm-related mortality was 92.1% at 30 days and 90.2% at 1 year. Freedom from patient-level VBX-related reintervention was 91.7%. Patient-level primary patency and secondary patency were 97.7% and 98.5%, respectively. Freedom from target vessel instability at the patient level was 90.4%. Conclusion: Short-term findings from this multicenter registry confirm that the VBX Stent Graft is a safe and effective bridging stent for BEVAR, demonstrating high technical success, excellent 1-year patency, and low rates of target vessel instability. Ongoing follow-up will evaluate mid-term durability. Clinical Impact Bridging stent performance is fundamental to the success of branched endovascular repair, yet multicenter, real-world data remain limited. This analysis from the EMBRACE registry demonstrates high technical reliability, excellent 1-year target vessel patency, and low rates of VBX Stent Graft-related reintervention. Technical failures were uncommon and were primarily associated with inadequate distal landing zones, highlighting the importance of procedural planning. These findings provide clinicians with contemporary evidence supporting the VBX Stent Graft as a safe and effective bridging stent for BEVAR and may inform procedural decision-making to optimize target vessel durability.
Authors
- Rocco Giudice (ORCID: https://orcid.org/0000-0002-2310-3825)
- Kaj Olav Kappe (ORCID: https://orcid.org/0009-0002-8636-8625)
- Marta Ascione (ORCID: https://orcid.org/0009-0002-0440-5032)
- Alessia Di Girolamo (ORCID: https://orcid.org/0000-0002-1933-1489)
- Luca di Marzo (ORCID: https://orcid.org/0000-0002-2956-6257)
- Giovanni Pratesi (ORCID: https://orcid.org/0000-0003-0174-3757)
- Enrico Rinaldi (ORCID: https://orcid.org/0000-0002-9501-0812)
- Timothy Andrew Resch (ORCID: https://orcid.org/0000-0001-8407-8216)
- Anders Wanhainen (ORCID: https://orcid.org/0000-0002-3273-8726)
- Márton Berczeli (ORCID: https://orcid.org/0000-0001-7591-5916)
- Antje Butter
- Luca Bertoglio (ORCID: https://orcid.org/0000-0001-6871-2176)
- Carlotta Bugna (ORCID: https://orcid.org/0009-0003-1301-8154)
- Kåre Christian Nordhus
- Angelos Karelis (ORCID: https://orcid.org/0000-0001-8971-658X)
- Luis Miguel Salmerón
- Ciro Ferrer (ORCID: https://orcid.org/0000-0003-0831-850X)
- Arjan W.J. Hoksbergen (ORCID: https://orcid.org/0000-0002-3140-5225)
- Jacob William Budtz-Lilly (ORCID: https://orcid.org/0000-0002-6181-6391)
- Nuno V. Dias (ORCID: https://orcid.org/0000-0002-6907-6148)
- Wassim Mansour (ORCID: https://orcid.org/0000-0002-7774-8178)
- Carlo Coscarella
- Frode Manstad-Hulaas (ORCID: https://orcid.org/0000-0002-4899-0248)
- Kak Khee Yeung (ORCID: https://orcid.org/0000-0002-8455-286X)
- Andrea Kahlberg (ORCID: https://orcid.org/0000-0003-1546-7159)
- Isaac Martinez Lopez
- Bergrós Jóhannesdóttir
- Nuno Dias
- Rocío Garralda
- Kevin Mani
- Rutger Lely
- Francisco Álvarez
- on behalf of EMBRACE study investigators (to be indexed on PubMed)
Institutions
- Uppsala University (SE)
- University of Copenhagen (DK)
- University Hospital of North Norway (NO)
- Vita-Salute San Raffaele University (IT)
- Azienda Ospedaliera San Giovanni Addolorata (IT)
- Policlinico Umberto I (IT)
- Haukeland University Hospital (NO)
- Aarhus University Hospital (DK)
- Rigshospitalet (DK)
- Hospital Clínico San Carlos (ES)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- St Olav's University Hospital (NO)
- Amsterdam Neuroscience (NL)
- IRCCS Ospedale San Raffaele (IT)
- Skåne University Hospital (SE)
- Ospedale Policlinico San Martino (IT)
- Amsterdam University of Applied Sciences (NL)
- University of Brescia (IT)
- University of Amsterdam (NL)
Publication Details
- Journal
- Journal of Endovascular Therapy
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1177/15266028261497969
- Primary Topic
- Aortic aneurysm repair treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00